CTX-M type beta-lactamase frequency and antibiotic co-resistance in extended spectrum beta-lactamase producing klebsiella pneumoniae strains;Genişlemiş spektrumlu beta-laktamaz üreten klebsiella pneumoniae suşlarında CTX-M tipi beta-laktamaz sıklıǧı ve antibiyotik ko-rezistansı

Turkiye Klinikleri Journal of Medical Sciences

Volumn 31, Issue 2, 2011, Pages 300-306

  Nazik, Hasan ^a   Öngen, Betigül ^a   Sarikaya, Aysel ^a   Kuvat, Nuray ^a   Ilktaç, Mehmet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bacterial; Drug resistance; Klebsiella pneumoniae

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE CTX M; CARBAPENEMASE; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; NITROFURANTOIN; NORFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DISK DIFFUSION; ENZYME SYNTHESIS; KLEBSIELLA PNEUMONIAE; NONHUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION;

EID: 80051754133     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: 10.5336/medsci.2010-19642     Document Type: Article

References (31)

1. Isturiz R. Global resistance trends and the potential impact on empirical therapy. Int J Antimicrob Agents 2008;32(Suppl 4):S201-6.
2. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007;59(2):165-74.
3. Cantón R, Coque TM. The CTX-M beta-lacta-mase pandemic. Curr Opin Microbiol 2006;9(5):466-75.
4. Gür D, Gülay Z, Akan OA, Aktaş Z, Kayacan CB, Cakici O, et al. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HI-TIT study]. Mikrobiyol Bul 2008;42(4):537-44.
5. Aktaş Z, Gönüllü N, Kayacan ÇB, Özdem A, Carattoli A, Yong DE, et al. [CTX-M-15 carried on Incn-type plasmids in Klebsiella pneumoniae]. Turkiye Klinikleri J Med Sci 2009;29(6):1355-64.
6. Yumuk Z, Afacan G, Nicolas-Chanoine MH, Sotto A, Lavigne JP. Turkey: a further country concerned by community-acquired Escherichia coli clone O25-ST131 producing CTX-M-15. J Antimicrob Chemother 2008;62(2):284-8.
7. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 2009;180(4):408-15.
8. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Nineteenth Informational Supplement. Document M100-S19. Vol 29 No 3, Wayne, PA: CLSI; 2009. p.1-153.
9. Nazik H, Ilktaç M, Ongen B. Prevalence of qnrA, qnrB, qnrS and aac(6')-Ib-cr (in qnr-po-sitive isolates) among ESBL-positive and/or ciprofloxacin-resistant isolates in Turkey. J Chemother 2009;21(2):219-21.
10. Pallecchi L, Bartoloni A, Fiorelli C, Mantella A, Di Maggio T, Gamboa H, et al. Rapid dissemination and diversity of CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-resource settings in Latin America. Antimicrob Agents Chemother 2007;51(8):2720-5.
11. Lartigue MF, Zinsius C, Wenger A, Bille J, Poirel L, Nordmann P. Extended-spectrum beta-lactamases of the CTX-M type now in Switzerland. Antimicrob Agents Chemother 2007;51(8):2855-60.
12. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB, et al. Extended-spec-trum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV-and CTX-M-type beta-lactamases. Anti-microb Agents Chemother 2003;47(11):3554-60.
13. Morosini MI, García-Castillo M, Coque TM, Valverde A, Novais A, Loza E, et al. Antibiotic coresistance in extended-spectrum-beta-lac-tamase-producing Enterobacteriaceae and in vitro activity of tigecycline. Antimicrob Agents Chemother 2006;50(8):2695-9.
14. Tikveşli S, Cevahir N, Kaleli I. [Investigation of CTX-M type beta-lactamases in K. pneumoniae clinical isolates by phenotypic and molecular methods]. Mikrobiyol Bul 2009;43(4):553-62.
15. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007;20(3):440-58.
16. Delialioǧlu N, Öcal ND, Emektaş G. [Rates of extended-spectrum beta-lactamase in Escherichia coli and Klebsiella species isolated from various clinical specimens]. Ankem Derg 2005;19(2):84-7.
17. Köseoǧlu O, Kocagöz S, Gür D, Akova M. Nosocomial bloodstream infections in a Turkish university hospital: study of Gram-negative bacilli and their sensitivity patterns. Int J Anti-microb Agents 2001;17(6):477-81.
18. Kucukates E. Antimicrobial resistance among Gram-negative bacteria isolated from intensive care units in a Cardiology Institute in Istanbul, Turkey. Jpn J Infect Dis 2005;58(4):228-31.
19. Günseren F, Mamikoǧlu L, Oztürk S, Yücesoy M, Biberoǧlu K, Yuluǧ N, et al. A surveillance study of antimicrobial resistance of gram-negative bacteria isolated from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother 1999;43(3):373-8.
20. Korten V, Ulusoy S, Zarakolu P, Mete B; Turkish MYSTIC Study Group. Antibiotic resistance surveillance over a 4-year period (2000-2003) in Turkey: results of the MYSTIC Program. Diagn Microbiol Infect Dis 2007;59(4):453-7.
21. Kacmaz B, Sultan N. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicill in-sulbactam and amoxicill in-clavul anic acid. Jpn J Infect Dis 2007;60(4):227-9.
22. Çetinkaya Z, Çiftçi İH, Aktepe OC, Şafak B, Altindiş M. [Antibiotic susceptibility of Klebsiell a strains isolated from clinical specimens]. Ankem Derg 2005;19(1):1-4.
23. Yildirim M, Şahin i, Gülcan A, Özdemir D, Küçükbayrak A, Uzun H, et al. [Antimicrobial susceptibility and uropathogens isolated from children and adults with community-acquired urinary tract infenctions]. Turkiye Klinikleri J Med Sci 2010;30(2):533-8.
24. Fedler KA, Biedenbach DJ, Jones RN. Assessment of pathogen frequency and resistance patterns among pediatric patient isolates: report from the 2004 SENTRY Antimicrobial Surveillance Program on 3 continents. Diagn Microbiol Infect Dis 2006;56(4):427-36.
25. Schwaber MJ, Navon-Venezia S, Schwartz D, Carmeli Y. High levels of antimicrobial coresistance among extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005;49(5):2137-9.
26. Akyar I. [Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital]. Mikrobiyol Bul 2008;42(4):713-5.
27. Martínez-Martínez L, Pascual A, Jacoby GA. Quinolone resistance from a transferable plasmid. Lancet 1998;351(9105):797-9.
28. Nazik H, Ongen B, Kuvat N. Investigation of plasmid-mediated quinolone resistance among isolates obtained in a Turkish intensive care unit. Jpn J Infect Dis 2008;61(4):310-2.
29. Nordmann P, Poirel L. Emergence of plasmid-mediated resistance to quinolones in Entero-bacteriaceae. J Antimicrob Chemother 2005;56(3):463-9.
30. Schito GC. Why fosfomycin trometamol as first line therapy for uncomplicated UTI? Int J Antimicrob Agents 2003;22(Suppl 2):79-83.
31. Göker G, Kaya I, Aydin D, Gürler N. [Investigation of Escherichia coli, Klebsiella and Ente-rococcus spp. susceptibilities to fosfomycine tromethamole in urinary tract infections]. Ankem Derg 2007;21(4):219-22.